Polymicrobial UTI with E. faecalis and MRSA: Initial Antimicrobial Therapy
For this polymicrobial urinary tract infection with both Enterococcus faecalis and MRSA that are both susceptible to nitrofurantoin, initiate nitrofurantoin 100 mg orally every 6 hours for 7 days, as it provides effective coverage against both organisms with excellent urinary concentrations and low resistance rates.
Rationale for Nitrofurantoin as First-Line
Nitrofurantoin achieves high urinary concentrations and demonstrates excellent in vitro activity against both E. faecalis (resistance rates below 6%) and MRSA, making it uniquely suited for this polymicrobial infection 1, 2, 3.
The susceptibility testing confirms both organisms are susceptible to nitrofurantoin (≤16 μg/mL for both), which falls well within the therapeutic range for urinary tract infections 3, 4.
Nitrofurantoin is FDA-approved for lower urinary tract infections and has been successfully used for treatment of UTIs caused by both Enterococcus species and Staphylococcus aureus 3.
Why Alternative Agents Are Less Optimal
Ampicillin/Amoxicillin Limitations
- While ampicillin 500 mg orally every 8 hours for 7 days is the preferred first-line agent for E. faecalis UTI with 88.1% clinical cure rates 1, 2, it has no activity against MRSA, leaving one pathogen untreated 5.
Vancomycin Limitations
- Although both organisms show vancomycin susceptibility (E. faecalis MIC 1 μg/mL, MRSA MIC ≤0.5 μg/mL), vancomycin has no oral formulation that achieves adequate urinary concentrations for UTI treatment and is reserved for IV use in serious systemic infections 1.
Trimethoprim-Sulfamethoxazole Considerations
- While both organisms show susceptibility to trimethoprim-sulfamethoxazole (≤10 μg/mL), this agent is not specifically recommended in current guidelines for enterococcal UTI and should be considered second-line 5.
Critical Clinical Algorithm
Assess for Complicated vs. Uncomplicated UTI
The presence of 2+ leukocyte esterase, 40-60 WBC/HPF, and trace protein suggests active infection rather than colonization 1, 2.
Look for complicating factors that would mandate longer therapy or IV treatment: fever >37.8°C, costovertebral angle tenderness, systemic symptoms (rigors, altered mental status), urinary retention, or recent instrumentation 5, 1.
Treatment Duration Considerations
For uncomplicated lower UTI with polymicrobial infection, 7 days of nitrofurantoin therapy is appropriate 1, 2.
Extend treatment to 10-14 days if complicating factors are present, including upper tract involvement, systemic symptoms, or underlying urological abnormalities 5, 1.
Important Caveats and Contraindications
Renal Function Requirements
Nitrofurantoin should not be used if creatinine clearance is <60 mL/min, as urinary concentrations become inadequate 1.
The question specifies normal renal function (CrCl ≥30 mL/min), but optimal efficacy requires CrCl ≥60 mL/min 1.
When Nitrofurantoin Cannot Be Used
Nitrofurantoin should not be used for complicated UTI, pyelonephritis, or any systemic enterococcal/staphylococcal infections (bacteremia, endocarditis), as it achieves poor tissue and serum concentrations 1, 2.
If upper tract involvement is suspected (fever, flank pain, costovertebral angle tenderness), initiate IV therapy with vancomycin 15-20 mg/kg every 8-12 hours to cover both organisms 5.
Monitoring and Follow-Up
Monitor for nitrofurantoin-associated adverse effects including pulmonary reactions, hepatic toxicity, and gastrointestinal disturbances 6.
Reassess clinical response at 48-72 hours; if symptoms persist or worsen, consider imaging to rule out upper tract involvement or abscess formation 5.
The low colony counts (10,000-49,000 CFU/mL for both organisms) combined with pyuria support true infection rather than contamination, but the presence of 6-10 squamous epithelial cells/HPF suggests possible specimen contamination 5.